A Phase IIa, Randomised, Double-blind, Placebo-controlled Study Using Outpatient Setting to Investigate the Duration of Effect and Evaluate Further Safety of PrEP-001 Given Prophylactically in Healthy Subjects, Subsequently Challenged With Human Rhinovirus (HRV-16)

Trial Profile

A Phase IIa, Randomised, Double-blind, Placebo-controlled Study Using Outpatient Setting to Investigate the Duration of Effect and Evaluate Further Safety of PrEP-001 Given Prophylactically in Healthy Subjects, Subsequently Challenged With Human Rhinovirus (HRV-16)

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Poly ICLC (Primary)
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Sponsors PrEP Biopharm
  • Most Recent Events

    • 15 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top